Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial

Author:

Gallwitz, B.; Rosenstock, J.; Patel, S.; von Eynatten, M.; Hehnke, U.; Mehlburger, L.; Dugi, K. A.; Woerle, H. -J.

Tübinger Autor(en):

Published in:

Diabetes Obesity & Metabolism (2015), Bd. 17, H. 3, S. 276-284

Verlagsangabe:

Wiley - Blackwell

Language:

English

Full text:

ISSN:

1462-8902

DDC Classifikation:

610 - Medicine and health

Dokumentart:

Artikel

This item appears in the following Collection(s)